SCHEMBL2348532

SCHEMBL2348532

CCC(=O)C(=O)Oc1c(-c2ccccc2)[nH]c2ccccc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.48
TUBB4A P04350 1/20 0.45
TUBB P07437 1/20 0.45
TUBA3C P0DPH7 1/20 0.45
TUBA1B P68363 1/20 0.45
TUBA4A P68366 1/20 0.45
TUBB4B P68371 1/20 0.45
TUBB3 Q13509 1/20 0.45
TUBB2A Q13885 1/20 0.45
TUBB8 Q3ZCM7 1/20 0.45
TUBA3E Q6PEY2 1/20 0.45
TUBA1A Q71U36 1/20 0.45
TUBA1C Q9BQE3 1/20 0.45
TUBB6 Q9BUF5 1/20 0.45
TUBB2B Q9BVA1 1/20 0.45
TUBB1 Q9H4B7 1/20 0.45
ESR1 P03372 1/20 0.45
ESR2 Q92731 1/20 0.45
KDM4E B2RXH2 1/20 0.44
MEN1 O00255 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2350012 0.83 ALDH1A1 (0.47) ALDH1A1KDM4EMEN1LMNAGAA
SCHEMBL6995871 0.81 TUBB4A (0.53) ALDH1A1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL5191713 0.74 MEN1 (0.48) ALDH1A1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL12466150 0.74 ESR1 (0.50) ALDH1A1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL6826115 0.72 TUBB4A (0.57) ALDH1A1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL13689695 0.71 USP2 (0.53) ALDH1A1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL28974916 0.70 TUBB4A (0.57) ALDH1A1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL10840435 0.70 ALDH1A1 (0.63) ALDH1A1KDM4EMEN1LMNAGAA
SCHEMBL27556713 0.70 GPR84 (0.44) ALDH1A1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL30482846 0.70 ALDH1A1 (0.76) ALDH1A1TUBB4ATUBBTUBA3CTUBA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1819697-B1 3-(INDOLYL)-4-ARYLMALEIMIDE DERIVATIVES AND THEIR USE AS ANGIOGENESIS INHIBITORS UNIV MAINZ JOHANNES GUTENBERG (DE) 2012-08-01 EP disclosed
US-8008320-B2 3-(indolyl)-4-arylmaleimide derivatives and their use as angiogenesis inhibitors Johannes Gutenberg-Universitatis (DE) 2011-08-30 US disclosed
US-20090306124-A1 3-(INDOLYL)-4-ARYLMALEIMIDE DERIVATIVES AND THEIR USE AS ANGIOGENESIS INHIBITORS JOHANNES GUTENBERG-UNIVERSITAT MAINZ (DE) 2009-12-10 US disclosed
EP-1819697-A1 3-(INDOLYL)-4-ARYLMALEIMIDE DERIVATIVES AND THEIR USE AS ANGIOGENESIS INHIBITORS Johannes Gutenberg-Universität Mainz (DE) 2007-08-22 EP disclosed
WO-2006061212-A1 3-(INDOLYL)-4-ARYLMALEIMIDE DERIVATIVES AND THEIR USE AS ANGIOGENESIS INHIBITORS Johannes Gutenberg-Universität Mainz (DE) 2006-06-15 WO disclosed
US-4598079-A MEMORY DISORDERS CASSELLA AKTIENGESELLSCHAFT (DE) 1986-07-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306124-A1 3-(INDOLYL)-4-ARYLMALEIMIDE DERIVATIVES AND THEIR USE AS ANGIOGENESIS INHIBITORS FLT4, KDR, FLT1 ALDH1A1 265/4885TUBB4A 1740/4885TUBB 2618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.